GlycoMimetics Initiates Phase 1/2 Clinical Trial of GMI-1271 as Potential Treatment for Acute Myeloid Leukemia in Combination with Chemotherapy
May 19, 2015 at 09:31 AM EDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that the first patient has been dosed in a Phase 1/2 clinical study designed to ...
